Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: A cost-effectiveness analysis

International Journal of Cancer

Volumn 128, Issue 8, 2011, Pages 1908-1917

  Van Rossum, Leo G M ^a   Van Rijn, Anne F ^b   Verbeek, Andre L M ^a   Van Oijen, Martijn G H ^c   Laheij, Robert J F ^c   Fockens, Paul ^b   Jansen, Jan B M J ^a   Adang, Eddy M M ^a   Dekker, Evelien ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cost effectiveness; faecal occult blood test; guaiac; immunochemical; mass screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GUAIAC FECAL OCCULT BLOOD TEST; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; OCCULT BLOOD; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; EARLY DETECTION OF CANCER; FEMALE; GUAIAC; HUMANS; IMMUNOENZYME TECHNIQUES; INDICATORS AND REAGENTS; MALE; MARKOV CHAINS; MIDDLE AGED; OCCULT BLOOD; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SURVIVAL RATE;

EID: 79951974767     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25530     Document Type: Article

References (44)

1. Pignone M, Saha S, Hoerger T, Mandelblatt J,. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104. (Pubitemid 34779153)
2. Woo PP, Kim JJ, Leung GM,. What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol 2007; 25: 617-24. (Pubitemid 350002915)
3. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM,. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284: 1954-61.
4. Sonnenberg A, Delco F, Inadomi JM,. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133: 573-84.
5. Vijan S, Hwang EW, Hofer TP, Hayward RA,. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001; 111: 593-601. (Pubitemid 34088068)
6. Joseph AM, Crowson TW, Rich EC,. Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening. J Gen Intern Med 1988; 3: 132-8.
7. Parekh M, Fendrick AM, Ladabaum U,. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008; 27: 697-712. (Pubitemid 351406306)
8. Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 2007; 132: 2304-12. (Pubitemid 46900821)
9. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E,. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90. (Pubitemid 351899018)
10. Blom J, Yin L, Liden A, Dolk A, Jeppsson B, Pahlman L, Holmberg L, Nyren O,. Toward understanding nonparticipation in sigmoidoscopy screening for colorectal cancer. Int J Cancer 2008; 122: 1618-23. (Pubitemid 351294972)
11. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J,. French colorectal cancer screening pilot programme: results of the first round. J Med Screen 2008; 15: 143-8.
12. Vernon SW,. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997; 89: 1406-22. (Pubitemid 27419204)
13. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, Caces ER,. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005; 115: 493-6. (Pubitemid 40663756)
14. Fisher DA, Jeffreys A, Coffman CJ, Fasanella K,. Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev 2006; 15: 1232-5.
15. Brouwer WB, Koopmanschap MA, Rutten FF,. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253-9. (Pubitemid 27296589)
16. Berchi C, Bouvier V, Reaud JM, Launoy G,. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ 2004; 13: 227-38. (Pubitemid 38292480)
17. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM,. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001; 135: 769-81. (Pubitemid 33051261)
18. Dutch National Cancer Registry database. Available at:. Accessed July 2009.
19. van Rossum LG, van Rijn AF, van Munster IP, Jansen JB, Fockens P, Laheij RJ, Dekker E,. Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests. Neth J Med 2009; 67: 182-6.
20. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, Waye JD, Bond J, Schapiro M, Stewart ET, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328: 901-6. (Pubitemid 23086641)
21. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E,. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006; 355: 1863-72. (Pubitemid 44664644)
22. Huppe D, Hartmann H, Felten G, Kemen M, Tannapfel A, Gillessen A, Katalinic A,. [Effectiveness of screening colonoscopy in a community-based study]. Zeitschrift fur Gastroenterologie 2008; 46: 193-200. (Pubitemid 351326482)
23. Atkin W,. Options for screening for colorectal cancer. Scand J Gastroenterol Suppl 2003: 13-6. (Pubitemid 36609872)
24. Dutch Health Care Authority database. Available at:. Accessed January 2009.
25. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR,. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159-68. (Pubitemid 27086806)
26. Mansmann U, Crispin A, Henschel V, Adrion C, Augustin V, Birkner B, Munte A,. Epidemiology and quality control of 245,000 outpatient colonoscopies. Dtsch Arztebl Int 2008; 105: 434-440.
27. Tulchinsky H, Madhala-Givon O, Wasserberg N, Lelcuk S, Niv Y,. Incidence and management of colonoscopic perforations: 8 years' experience. World J Gastroenterol 2006; 12: 4211-3. (Pubitemid 44376905)
28. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, Schulman J,. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006; 145: 880-6. (Pubitemid 351639963)
29. Statistics Netherlands. Available at:. Accessed January 2009.
30. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, Verbeek AL, Dekker E,. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009; 101: 1274-81.
31. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 100: 259-65.
32. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y,. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55. (Pubitemid 351650610)
33. Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah AS, Zhang B,. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999; 46: 228-31. (Pubitemid 29154752)
34. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92. (Pubitemid 46359643)
35. Song K, Fendrick AM, Ladabaum U,. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004; 126: 1270-9. (Pubitemid 38552791)
36. Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M,. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002; 9: 99-103. (Pubitemid 35205230)
37. Hardcastle JD, Armitage NC, Chamberlain J, Amar SS, James PD, Balfour TW,. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer 1986; 58: 397-403. (Pubitemid 16058622)
38. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ,. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Instit 2009; 101: 1412-22.
39. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME,. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 100: 1103-10.
40. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM,. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7. (Pubitemid 32162983)
41. Edwards JT, Mendelson RM, Fritschi L, Foster NM, Wood C, Murray D, Forbes GM,. Colorectal neoplasia screening with CT colonography in average-risk asymptomatic subjects: community-based study. Radiology 2004; 230: 459-64. (Pubitemid 38133807)
42. Edwards JT, Wood CJ, Mendelson RM, Forbes GM,. Extracolonic findings at virtual colonoscopy: implications for screening programs. Am J Gastroenterol 2001; 96: 3009-12. (Pubitemid 32959546)
43. Schwartz RN,. Management of early and advanced colorectal cancer: therapeutic issues. Am J Health Syst Pharm 2008; 65: S8-14. (Pubitemid 351768724)
44. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML,. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Instit 2008; 100: 888-97. (Pubitemid 351881955)